Sponsored by Gilead Sciences, Inc.
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B
Article first published online: 6 NOV 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 59, Issue 2, pages 434–442, February 2014
How to Cite
Kitrinos, K. M., Corsa, A., Liu, Y., Flaherty, J., Snow-Lampart, A., Marcellin, P., Borroto-Esoda, K. and Miller, M. D. (2014), No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology, 59: 434–442. doi: 10.1002/hep.26686
Potential conflict of interest: Dr. Corsa owns stock in Gilead. Dr. Snow-Lampart owns stock in Gilead. Dr. Flaherty owns stock in Gilead. Dr. Kitrinos owns stock in Gilead. Dr. Miller owns stock in Gilead. Dr. Liu owns stock in Gilead.
- Issue published online: 29 JAN 2014
- Article first published online: 6 NOV 2013
- Accepted manuscript online: 12 AUG 2013 05:41AM EST
- Manuscript Accepted: 5 AUG 2013
- Manuscript Received: 9 DEC 2012
Additional Supporting Information may be found in the online version of this article.
|hep26686-sup-0001-suppinfo.eps||376K||Supporting Figure 1: Patients with LAM-R and/or ADV-R detected while on TDF or FTC/TDF. Conserved-site changes are noted in bold italics; all other changes are polymorphic. The black box in the treatment window indicates timepoints where the patient was documented to be nonadherent to study medication.|
|hep26686-sup-0002-suppinfo.docx||19K||Supporting Table 1. Resistance Surveillance Population: Number of Patients Qualifying for Genotypic Analysis at Their Last Visit on TDF or FTC/TDF|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.